CEL Competitive ELISA

CEL Competitive ELISA
  • Provides rapid detection and quantitation of CEL protein adducts
  • Perform up to 96 assays, including standard curve and unknown protein samples
  • Will not cross react with CML protein adducts

 

Video: Color Development in an ELISA

Email To BuyerPrint this PageCopy Link
Ordering

Please contact your distributor for pricing.

OxiSelect™ N-epsilon-(Carboxyethyl) Lysine (CEL) Competitive ELISA
Catalog Number
STA-813
Size
96 assays
Detection
Colorimetric
Manual/Data Sheet Download
SDS Download
Price
$725.00
OxiSelect™ N-epsilon-(Carboxyethyl) Lysine (CEL) Competitive ELISA
Catalog Number
STA-813-5
Size
5 x 96 assays
Detection
Colorimetric
Manual/Data Sheet Download
SDS Download
Price
$3,125.00
Product Details

OxiSelect™ Nε-(carboxyethyl) lysine (CEL) ELISA Kit provides rapid detection and quantitation of CEL protein adducts. First, a CEL conjugate is coated on the ELISA plate.  The unknown CEL protein samples or CEL-BSA standards are then added to the CEL conjugate preabsorbed plate.  After a brief incubation, the anti-CEL monoclonal antibody is added, followed by an HRP conjugated secondary antibody.  The content of CEL protein adducts in unknown samples is determined by comparison with the predetermined CEL-BSA standard curve.  Despite the structure similarity between CEL and CML, the anti-CEL specific antibody in the OxiSelect™ CEL ELISA Kit will not cross react with CML protein adducts.

Recent Product Citations
  1. Shen, C.Y. et al. (2023). Unveiling the molecular basis of inflamm-aging induced by advanced glycation end products (AGEs)-modified human serum albumin (AGE-HSA) in patients with different immune-mediated diseases. Clin Immunol. 252:109655. doi: 10.1016/j.clim.2023.109655.
  2. Damasiewicz-Bodzek, A. & Nowak, A. (2022). Concentrations of N6-Carboxymethyllysine (CML), N6-Carboxyethyllysine (CEL), and Soluble Receptor for Advanced Glycation End-Products (sRAGE) Are Increased in Psoriatic Patients. Biomolecules. 12(12):1870. doi: 10.3390/biom12121870.
  3. Drygalski, K. et al. (2021). Phloroglucinol prevents albumin glycation as well as diminishes ROS production, glycooxidative damage, nitrosative stress and inflammation in hepatocytes treated with high glucose. Biomed Pharmacother. 142:111958. doi: 10.1016/j.biopha.2021.111958.
  4. Kaburagi, T. et al. (2019). Low-Carbohydrate Diet Inhibits Different Advanced Glycation End Products in Kidney Depending on Lipid Composition but Causes Adverse Morphological Changes in a Non-Obese Model Mice. Nutrients. 11(11). pii: E2801. doi: 10.3390/nu11112801.
  5. Nakamura, T. et al. (2019). Poorly controlled type 2 diabetes with no progression of diabetes-related complications and low levels of advanced glycation end products: A Case report. Medicine (Baltimore). 98(30):e16573. doi: 10.1097/MD.0000000000016573.
  6. Li, C.T. et al. (2018). Effects of glycation on human γd-crystallin proteins by different glycation-inducing agents. Int J Biol Macromol. 118(Pt A):442-451. doi: 10.1016/j.ijbiomac.2018.06.108.
  7. Cannizzaro, L. et al. (2017). Regulatory landscape of AGE-RAGE-oxidative stress axis and its modulation by PPARγ activation in high fructose diet-induced metabolic syndrome. Nutr Metab (Lond). 14:5. doi: 10.1186/s12986-016-0149-z.
  8. Morgan, P. E. et al. (2014). Perturbation of human coronary artery endothelial cell redox state and NADPH generation by methylglyoxal. PLoS One. 9:e86564.